2.19
前日終値:
$2.12
開ける:
$2.14
24時間の取引高:
1.06M
Relative Volume:
0.74
時価総額:
$97.10M
収益:
-
当期純損益:
$-97.22M
株価収益率:
-1.587
EPS:
-1.38
ネットキャッシュフロー:
$-82.44M
1週間 パフォーマンス:
+8.96%
1か月 パフォーマンス:
+45.03%
6か月 パフォーマンス:
-31.99%
1年 パフォーマンス:
-89.02%
Cassava Sciences Inc Stock (SAVA) Company Profile
名前
Cassava Sciences Inc
セクター
電話
512-501-2444
住所
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
SAVA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SAVA
Cassava Sciences Inc
|
2.19 | 97.10M | 0 | -97.22M | -82.44M | -1.38 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-26 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2024-10-08 | アップグレード | H.C. Wainwright | Neutral → Buy |
2024-07-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2022-11-16 | ダウングレード | B. Riley Securities | Buy → Neutral |
2021-07-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2021-07-07 | 繰り返されました | Maxim Group | Buy |
2021-04-27 | 開始されました | B. Riley Securities | Buy |
2021-02-16 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
2020-09-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
2020-05-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2020-05-15 | ダウングレード | Maxim Group | Buy → Hold |
2020-01-10 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Cassava Sciences Inc (SAVA) 最新ニュース
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
BNP Paribas Financial Markets Buys 55,813 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
Cassava Sciences Holds 2025 Annual Meeting, Elects Directors - TipRanks
Transcript : Cassava Sciences, Inc.Shareholder/Analyst Call - marketscreener.com
Cassava Sciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationSAVA - ACCESS Newswire
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA)February 10, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Reports Q1 2025 Financials Results, Provides Business Update - GlobeNewswire
Cassava Sciences Shifts Focus to TSC-Related Epilepsy - TipRanks
Cassava Sciences (SAVA) Faces Financial Challenges Amid Strategic Shifts - GuruFocus
Invesco Ltd. Trims Stock Position in Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Cassava Sciences (SAVA) Appoints New SVP of Neuroscience | SAVA Stock News - GuruFocus
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC - citybiz
Investors who Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class ActionSAVA - ACCESS Newswire
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Cassava Sciences Inc (SAVA) 財務データ
収益
当期純利益
現金流量
EPS
Cassava Sciences Inc (SAVA) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
大文字化:
|
ボリューム (24 時間):